← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
University Of Virginia Charlottesville
Charlottesville, VA
$697,314,202
Total funding
1,319
Grants
Funding mix
By agency
NIH$699,148,759 · 1314
AHRQ$0 · 4
CDC$0 · 2
By mechanism
R01$453,698,273 · 478
M01$35,118,803 · 256
T32$34,540,840 · 26
P01$32,423,252 · 85
R21$20,225,242 · 60
R37$20,121,198 · 16
Investigators at University Of Virginia Charlottesville
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Cell Migration Consortium$7,964,455
U54 · FY2001 · GM
Cell Migration Consortium$7,824,064
U54 · FY2005 · GM
Cell Migration Consortium$7,633,227
U54 · FY2004 · GM
Cell Migration Consortium$7,358,490
U54 · FY2003 · GM
Cell Migration Consortium$7,084,584
U54 · FY2002 · GM
GENERAL CLINICAL RESEARCH CENTER$4,347,418
M01 · FY2002 · RR
GENERAL CLINICAL RESEARCH CENTER$4,235,100
M01 · FY2004 · RR
GENERAL CLINICAL RESEARCH CENTER$4,162,175
M01 · FY2003 · RR
GENERAL CLINICAL RESEARCH CENTER$4,095,808
M01 · FY2001 · RR
GENERAL CLINICAL RESEARCH CENTER$3,856,880
M01 · FY2000 · RR
GENERAL CLINICAL RESEARCH CENTER$3,715,218
M01 · FY2005 · RR
CENTER FOR RECOMBINANT GAMETE CONTRACEPTIVE VACCINOGENS$2,363,015
U54 · FY2001 · HD
CENTER FOR RECOMBINANT GAMETE CONTRACEPTIVE VACCINOGENS$2,041,686
U54 · FY2000 · HD
Glucose, Insulin in Diabetic Vascular Disease$2,019,412
P01 · FY2005 · HL
Dopamine/Angiostensin Receptors in Genetic Hypertension$1,987,142
P01 · FY2004 · HL
CANCER CENTER SUPPORT GRANT$1,982,572
P30 · FY2003 · CA
Dopamine/Angiostensin Receptors in Genetic Hypertension$1,981,272
P01 · FY2005 · HL
9.4 Tesla MR Scanner for Murine Imaging$1,980,000
S10 · FY2005 · RR
Glucose, Insulin in Diabetic Vascular Disease$1,962,709
P01 · FY2004 · HL
CANCER CENTER SUPPORT GRANT$1,959,831
P30 · FY2000 · CA